Barington Capital has escalated its campaign at Chemed (CHE), pressing the board to launch a strategic review, cut executive perks, and refresh governance. These moves put fresh attention on how the company allocates capital.

Chemed’s share price has moved to US$511.13, with a 1 month share price return of 10.33% and a 3 month share price return of 21.38%. The 1 year total shareholder return of 10.26% contrasts with a slightly negative 3 year total shareholder return, hinting that recent momentum is stronger than the longer term record as investors weigh both the activist pressure and the upcoming earnings update.

If this kind of catalyst driven story interests you, it can be useful to see what else is moving and uncover 18 top founder-led companies

For Chemed, a 10% one month gain and activist pressure arriving just before earnings blur the line between business fundamentals and changing sentiment. How much of today’s US$511 share price reflects each side of that story?

Most Popular Narrative: 8% Overvalued

Chemed is trading at $511.13 against a widely followed fair value estimate of $474, so the current price sits above that narrative anchor while activist pressure and upcoming earnings keep expectations in flux.

The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (e.g., Pinellas and Marion) is expected to materially expand VITAS's service footprint, aligning with the continued aging U.S. population and the shift toward home-based care, both key drivers of higher patient volumes and long-term top-line revenue growth.

Want to see what this growth story assumes for Chemed’s revenue mix, margins and future multiple? The narrative leans on steady expansion, richer profitability and shrinking share count to justify that fair value.

Result: Fair Value of $474 (OVERVALUED)

However, the Chemed narrative still hinges on Medicare reimbursement exposure at VITAS and weaker residential demand at Roto-Rooter, both of which could quickly reset expectations.

Another View: Chemed Through the SWS DCF Model

The earlier narrative framed Chemed as 8% overvalued versus a US$474 fair value anchor. Our DCF model points in the opposite direction, with a future cash flow value of about US$706.80 per share, which is above the current US$511.13 price.

This gap suggests the DCF view is baking in stronger cash generation than the analyst multiple based fair value. For you as an investor, the question is which story feels more realistic: the market leaning toward the US$474 anchor, or the cash flow path implied by US$706.80.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Chemed for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With activists involved and valuation signals pulling in different directions, sentiment on Chemed is clearly split. Consider reviewing the underlying numbers yourself, then weigh up the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Chemed?

If you are weighing what comes next after Chemed, do not stop with a single stock story. Widen your watchlist while this market is still offering options.

• Target steadier opportunities by checking out 84 resilient stocks with low risk scores that aim to keep volatility in check while you stay focused on the long term.
• Hunt for quality at a discount with the screener containing 20 high quality undiscovered gems before they sit firmly on everyone else's radar.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (49 results) so your portfolio leans on sturdier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.